Aug 2026· European journal of medicinal chemistry· Vol 318, pp.
119216
· 0 citations· 43 references
Medicine
TL;DR
Through a fragment recombination approach utilizing P2Y2R privileged fragments to explore non-additive SAR trends in combination with molecular docking studies, a series of potent uracil-based P2Y2R antagonists are discovered, such as compound 26a.
Abstract
Antagonism of purinergic P2Y2 receptors offers potential benefits in the treatment of inflammatory diseases, neurodegenerative disorders, and cancer. Despite the promising preclinical potential, only a limited number of potent and selective non-nucleotide P2Y2R antagonists are known, including AR-C118925, which has been extensively used to study inhibition of the P2Y2R. However, unfavorable physicochemical properties and the presence of a reactive and photo-unstable 4-thiouracil moiety have limited their preclinical progress. Through a fragment recombination approach utilizing P2Y2R privileged fragments to explore non-additive SAR trends in combination with molecular docking studies, we discovered a series of potent uracil-based P2Y2R antagonists, such as compound 26a (pKi (whole cells) 6.55 ± 0.05). Molecular docking of 26a led to rationalization of the unexpected affinity for 26a, and led to the identification of new stable, uracil-based fluorescent ligands targeting the P2Y2R.
Virtual screening was employed to identify natural product-derived candidates with potential P2X7 receptor antagonistic activity and suggest that compound C71 acts as a promising P2X7 receptor inhibitor capable of blocking ATP-induced pore formation and downstream oxidative signaling, supporting further investigation a...
N. C. da Silva Ferreira, L. Lima, Nicole de Menezes Macedo et al.· Biomedicine & pharmacotherap...· 0 citations
Cytochrome P450 1B1 (CYP1B1) is selectively overexpressed in various tumor cells and plays a critical role in the metabolic inactivation of chemotherapeutic agents, leading to drug resistance. Therefore, the development of selective CYP1B1 inhibitors represents a promising strategy to overcome chemoresistance. In this...
To continue our research on developing PPO inhibitors, we replaced the triazinone core of compounds B, G, and H from our previous work with pyrimidinediones, employing a scaffold-hopping strategy to design and synthesize compounds I, J, and K. Compound I18 exhibited potent NtPPO inhibition (Ki = 10.9 nM) and broad-sp...
Wei Zhang, Ke-Shi Luo, Di Li et al.· Journal of Agricultural and...· 0 citations
This results identify BDM-3 as a computationally prioritized analog with favorable predicted CYP1A2 interaction, pharmacokinetic characteristics, and drug-like properties, with broader relevance to the development and optimization of anticancer drug candidates.
Aqsa Laraib, Muhammad Husnain, M. Alshahrani et al.· Journal of Pharmaceutical In...· 0 citations
Alzheimer's disease (AD) remains a multifactorial neurodegenerative disorder and currently there are only a few symptomatic therapies available to treat the cholinergic system. The pyrimidine scaffold has become a privileged scaffold for the design of multi-target directed ligands (MTDLs) that are effective at targetin...
Salahuddin S, Lovely Lovely, Mukesh Kumar Singh et al.· Oriental Journal of Chemistr...· 0 citations
